文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

载脂蛋白(a)与杂合子家族性高胆固醇血症患者前蛋白转化酶枯草溶菌素 9 之间的关系:一项病例对照研究。

Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.

机构信息

Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China.

Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China.

出版信息

Metabolism. 2018 Feb;79:33-41. doi: 10.1016/j.metabol.2017.11.004. Epub 2017 Nov 10.


DOI:10.1016/j.metabol.2017.11.004
PMID:29129821
Abstract

BACKGROUND: Recent data have suggested an important role of lipoprotein (a) [Lp(a)] and proprotein convertase substilisin/kexin type 9 (PCSK9) in the development of atherosclerotic cardiovascular disease (ASCVD) in both general population and family hypercholesterolemia (FH), while the relation of Lp(a) to PCSK9 has not been examined. OBJECTIVE: The aim of the present study was to investigate the association between plasma PCSK9 and Lp(a)in patients with heterozygous FH (HeFH). METHODS: Two hundred and fifty-five molecularly confirmed patients with HeFH were compared to 255 age- and gender-matched non-FH controls. Plasma PCSK9 and Lp(a) concentrations were measured using ELISA and immunoturbidimetric method respectively, and finally their association was assessed. RESULTS: Both plasma PCSK9 and Lp(a) levels were significantly higher in patients with HeFH compared to control group (p<0.001). Besides, the Lp(a) concentration and percentage of Lp(a)≥300mg/L were increased by PCSK9 tertiles in HeFH group (both p<0.05) while not in control group. In partial correlation analysis, Lp(a) was associated with PCSK9 (r=0.254, p<0.001) in HeFH group but not in control, which were further confirmed by multivariable linear regression analysis. Furthermore, significant associations between Lp(a) and PCSK9 were also found in subgroups of HeFH group irrespective of definite or probable FH, with and without coronary artery disease (CAD), and with statin or not. CONCLUSIONS: Plasma Lp(a) level was associated with PCSK9 in patients with HeFH alone, suggesting that much about the interaction of PCSK9 with Lp(a) in FH need further explorations.

摘要

背景:最近的数据表明,脂蛋白(a)[Lp(a)]和前蛋白转化酶枯草溶菌素/ kexin 9 型(PCSK9)在普通人群和家族性高胆固醇血症(FH)的动脉粥样硬化性心血管疾病(ASCVD)的发展中起着重要作用,而 Lp(a)与 PCSK9 的关系尚未得到检验。

目的:本研究旨在探讨杂合子 FH(HeFH)患者血浆 PCSK9 与 Lp(a)的相关性。

方法:将 255 例经分子证实的 HeFH 患者与 255 例年龄和性别匹配的非 FH 对照组进行比较。采用 ELISA 和免疫比浊法分别测定血浆 PCSK9 和 Lp(a)浓度,最后评估其相关性。

结果:HeFH 组患者的血浆 PCSK9 和 Lp(a)水平均显著高于对照组(p<0.001)。此外,HeFH 组中,PCSK9 三分位的 Lp(a)浓度和 Lp(a)≥300mg/L 的比例均升高(p<0.05),而对照组无此变化。在偏相关分析中,HeFH 组中 Lp(a)与 PCSK9 相关(r=0.254,p<0.001),但对照组无此相关性,多变量线性回归分析进一步证实了这一点。此外,在 HeFH 组的亚组中,无论 FH 是确定的还是可能的,有无冠心病(CAD),是否使用他汀类药物,均发现 Lp(a)与 PCSK9 之间存在显著相关性。

结论:仅在 HeFH 患者中,血浆 Lp(a)水平与 PCSK9 相关,提示 FH 中 PCSK9 与 Lp(a)的相互作用需要进一步探讨。

相似文献

[1]
Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.

Metabolism. 2017-11-10

[2]
The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.

Atherosclerosis. 2018-7-26

[3]
Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.

Atherosclerosis. 2018-10

[4]
Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.

J Clin Lipidol. 2017

[5]
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.

Circ J. 2016

[6]
Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.

J Am Coll Cardiol. 2014-3-12

[7]
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.

Atherosclerosis. 2016-11

[8]
Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.

J Clin Lipidol. 2017-10-12

[9]
The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.

Metabolism. 2015-8-20

[10]
Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.

J Diabetes Complications. 2015

引用本文的文献

[1]
Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention.

Metabolites. 2022-11-4

[2]
Risk Stratification in Familial Hypercholesterolemia: Do Severe Phenotypes Have Clinically Worse Outcomes in Asia Population?

JACC Asia. 2021-9-21

[3]
Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part II. Clinical Characteristics.

Front Genet. 2022-3-14

[4]
Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters.

Front Genet. 2022-2-28

[5]
Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a.

J Transl Med. 2020-5-12

[6]
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy.

J Transl Med. 2019-11-11

[7]
Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review.

Curr Cardiol Rev. 2020

[8]
Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?

Curr Atheroscler Rep. 2019-3-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索